M.C. Rousselet

Screening for therapeutic trials and treatment indication in clinical practice: <scp>MACK</scp>‐3, a new blood test for the diagnosis of fibrotic <scp>NASH</scp>

Jérôme Boursier, Rodolphe Anty, Luisa Vonghia et al. · Alimentary Pharmacology & Therapeutics · 2018 · 74 citations · Full text

Medicine, Internal Medicine, Pathology +17

Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver‐prognosis in chronic hepatitis C

Jérôme Boursier, Charlène Brochard, Sandrine Bertrais et al. · Alimentary Pharmacology & Therapeutics · 2014 · 40 citations · Full text

Medicine, Internal Medicine, Pathology +17

Long-term follow-up of a randomized trial of fludarabine–mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies

C. Foussard, Philippe Colombat, Hervé Maisonneuve et al. · Annals of Oncology · 2005 · 18 citations · Full text

Medicine, Oncology, Pharmacology +14

Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study

Corentin Orvain, Damien Luque Paz, Irène Dobo et al. · Annals of Hematology · 2016 · 14 citations

Medicine, Hematology, Pathology +14

Use and benefits of COTS board level testing for radiation hardness assurance

M.C. Rousselet, Philippe C. Adell, Doug Sheldon et al. · 2016 · 13 citations

Engineering, Aerospace Engineering, Electrical Engineering +17